ClinicalTrials.gg
CompletedNCT04210375Updated Jul 9, 2025Results posted

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

A Phase 1 interventional study of JK07 and Matching Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Salubris Biotherapeutics Inc. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Salubris Biotherapeutics Inc (part of Shenzhen Salubris Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,316th of 1,601
14 · median 65
Started
2020
with 97 others
Phase 1
118 of 2,157
18 open now
Registered
1,444th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,316th largest by enrollment of the 1,601 interventional ones that give a count, is one of 98 that started in 2020, is one of 118 in phase 1, and was the 1,444th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF ≤40%.

Initially 5 cohorts are planned with the option to expand the study to a total of 7 cohorts. The size of the cohorts will range from 5 to 9 subjects. Each cohort will include one single active unblinded sentinel subject receiving a single IV dose of JK07 prior to randomized single dose administration of JK07 or placebo [3:1] in the remainder of the cohort.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in HF subjects 18 to 80 years of age with LVEF ≤40%. Subjects must have been maintained on an optimal HF medical regimen for at least 2 months prior to enrollment and remain on the same treatment regimen throughout the course of the study, per the 2017 ACC/AHA/HFSA) treatment guidelines.

At screening, eligible subjects will undergo a physical examination, 2-dimensional transthoracic echocardiography (2D-TTE), ECG assessment, blood sampling for laboratory parameters, and urine testing. Safety assessments at screening will include hematology, biochemistry, coagulation, liver, and thyroid function.

Subjects will be observed in the hospital on continuous telemetry from the time of hospital admission until shortly before discharge approximately 48 hours later. During this time, they will additionally have safety labs, vital signs, PK and biomarker samples collected, and ECGs and 2D-TTEs performed.

Only a single dose of the investigational product will be administered and only a single hospital admission is planned per subject during the study. Subjects will complete follow-up visits through 180 days after administration of the investigational product.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • heart failure
  • HFrEF
  • neuregulin 1
  • NRG-1
  • heregulin
  • HER3
  • HER4
  • ErbB3
  • ErbB4
  • reduced ejection fraction
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 and 80 years with stable Class II or III HF diagnosis (ischemic or non-ischemic confirmed by medical history) at least 6 months prior to enrollment as confirmed by medical history.
  2. Stable HF defined as no hospitalizations for cardiac-related issues within the previous 2 months prior to the screening visit or between screening and randomization, other than for routine percutaneous procedures such as device, battery, generator changes or pacemaker lead insertion/ replacement.
  3. Subjects with clearly interpretable echocardiographic images and with a screening ≤ 40% in the absence of ≥ Grade 3 valvular disease on 2D-TTE.
  4. Subjects must be taking clinician-directed appropriate pharmacological therapy for HF as per the 2017 ACC/AHA/HFSA treatment guidelines at stable doses and at investigator determined discretion (except for diuretics) for at least 2 months prior to .
  5. Subjects with implantable cardioverter-defibrillators (ICDs) are allowed at the discretion of the investigator, but only if both the following criteria are met: (a) paced beats cannot exceed 15% of beats as quantified by screening e-Patch, and (b) if a non-paced baseline can be obtained on day 1 prior to study drug administration.

5. ≥18 kg/m2 and ≤45 kg/m2. 6. Screening ≥9.0 g/dL, ≥100 K/mL, ≥1500/mL. 7. Able and willing to use adequate until the end of the study.

8. Capable of providing informed consent and to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participating in any other study, have received any other drug within 30 days prior to screening or 5-half-lives or any other investigational implanted device within 30 days prior to screening, or are taking part in a nonmedication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments.
  2. Any past participation in a study that has investigated the NRG-1 pathway (e.g., Neucardin, Cimaglermin).
  3. Heart failure due to hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricula dysplasia (ARVD), stress-induced ("Takotsubo") cardiomyopathy, chemotherapy-induced cardiomyopathy, peripartum cardiomyopathy, infiltrative or inflammatory cardiomyopathies, and primary valvular disease.
  4. Medically documented acute coronary syndrome within 3 months of screening or a medically documented acute MI within 6 months of screening.
  5. Cardiac surgery, coronary artery revascularization, percutaneous coronary intervention, or valvuloplasty within 3 months prior to screening.
  6. Any subject who has received an indication for coronary revascularization within 3 months prior to screening.
  7. Any major surgical procedure within 1 month prior to screening or planned surgical procedure during the study period.
  8. Sustained systolic blood pressure \<90 mm Hg and/or diastolic blood pressure \<50 mm Hg.
  9. Sustained resting heart rate >100 beats per minute sustained for >15 minutes except in sustained atrial fibrillation when a heart rate of up to 110 beats per minute is acceptable.
  10. Cerebrovascular accident or hospitalizations for CV (cardiovascular) causes other than routine percutaneous procedures such as device, battery, generator changes or pacemaker lead insertion/ replacement or device generator changes, including HF, chest pain, stroke, , or arrhythmias within 3 months prior to randomization.
  11. At screening have an abnormal or 12-lead abnormality that, in the opinion of the Investigator, would affect efficacy or safety evaluation or place the subject at risk.
  12. History or evidence of clinically significant arrhythmia uncontrolled by drug therapy or use of an implantable defibrillator, long syndrome, or evidence of QT prolongation with QTcF >450 ms for males or QTcF >470 ms for females prior to randomization.
  13. Clinically significant renal dysfunction as measured by the estimated \<45 mL/min/1.73m2 at screening, or a clinically significant change in renal function between screening and baseline.
  14. Clinically significant liver dysfunction as measured by: >2.0 × , alkaline phosphatase > 2.0 × ULN, AST >2.0 × the ULN, or GGT >2.0 × the ULN or serum ≥ 1.2 × the ULN at screening, or a clinically significant change in liver function between screening and baseline.
  15. Subjects with alteration of the coagulation panel () and/or PT ≥ 1.5 × the ULN; aPTT ≥ 1.5 × ULN, or serum albumin ≤ 3 gm/dL. For subjects on warfarin or other anticoagulants, an INR (or PT) considered by the Principal Investigator as therapeutically appropriate will be allowed.
  16. Subjects with values of CPK and/or CK-MB >2.5 times normal institutional limits at screening.
  17. Any subject who by Investigator's judgement, has a significant hematuria or proteinuria at screening.
  18. Concurrent treatment with Class Ia or III antiarrhythmic drugs (the medication must have been discontinued more than 2 months before ).
  19. Positive screening for antibodies, surface antigen, or virus antibodies.
  20. Known history of or active alcohol abuse (no more than 14 units/week for males or 7 units/week for females) or use of illicit drugs within 1 year prior to randomization (excluding recreational use of marijuana or cannabidiol [CBD]-based products.
  21. Other medical or psychiatric condition that, in the opinion of the Investigator, would preclude obtaining voluntary consent/assent or would confound the secondary objectives of study.
  22. A history of -confirmed of any type or any pathologically-confirmed pre-malignant condition (e.g. ductal carcinoma in situ, colonic polyp with premalignant diagnosis, or cervical atypia).
  23. Pregnant or lactating female subjects at screening.
  24. Subjects with clinically significant or poorly controlled disease including, but not limited to, endocrine (including diabetes and thyroid) disease, neurological or psychiatric (even mild), GI, hematological, urological, immunological, or ophthalmic diseases as determined by the Investigator.
  25. Subjects who are not non-smokers or light smokers (no more than 5 cigarettes per day) and who cannot abstain from smoking from 2 weeks prior to the administration of IP through the end of the study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    JK07

    Single dose of JK07 administered by intravenous infusion over 60 minutes

    Drug: JK07

  • Placebo comparator
    Matching Placebo

    Single dose of placebo administered by intravenous infusion over 60 minutes

    Drug: Matching Placebo

Interventions

  • DrugJK07

    Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

  • DrugMatching Placebo

    Vehicle control

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]

    All safety information is collected and evaluated.

    Time frame: Screening to 30 days

Secondary outcomes

  1. AUC(0-last) of JK07

    Area under the concentration (time curve to the last quantifiable concentration) from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

    Time frame: Baseline to 60 days

  2. Cmax of JK07

    Maximum concentration from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

    Time frame: Baseline to 60 days

  3. t1/2 of JK07

    Half-life from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

    Time frame: Baseline to 60 days

Other outcomes

  1. Left Ventricular Ejection Fraction (LVEF)

    2D-transthoracic echocardiography-derived LVEF

    Time frame: Screening to 180 days

07

Results

Posted Jul 9, 2025
Limitations and caveats
This was a Phase 1, single ascending dose study intended to support the continued exploration of JK07 as a HF treatment. As such, these results provide only a very early picture of the potential safety profile and pharmacodynamics of JK07.

Participant flow

Participant flow — Overall Study
MilestoneJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching Placebo
Started4433
Completed4333
Not completed0100
Withdrew: Death0100

Outcome measures

PrimaryIncidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]

All safety information is collected and evaluated.

Time frame:
Screening to 30 days
Reported as:
Number · number of events
Incidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]
number of eventsJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching Placebo
Treatment emergent AEs4382
SAEs0010
SecondaryAUC(0-last) of JK07

Area under the concentration (time curve to the last quantifiable concentration) from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

Time frame:
Baseline to 60 days
Reported as:
Geometric mean · h*ng/mL
AUC(0-last) of JK07
h*ng/mLJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3
AUC(0-last) of JK075310 ± 80.634400 ± 2.9139000 ± 15.1
Other pre-specifiedLeft Ventricular Ejection Fraction (LVEF)

2D-transthoracic echocardiography-derived LVEF

Time frame:
Screening to 180 days
Reported as:
Mean · % of LVEF
Left Ventricular Ejection Fraction (LVEF)
% of LVEFJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching Placebo
Day 1 - pre dose34 (29 to 36)28 (21 to 32)25 (17 to 37)31 (28 to 37)
Day 1 - 6 hrs post dose37 (34 to 39)30.5 (19 to 40)31 (23 to 35)33.7 (29 to 43)
Day 239.8 (37 to 44)28.8 (21 to 41)30.7 (20 to 39)32.3 (32 to 33)
Day 738.5 (29 to 51)33.5 (26 to 40)28 (21 to 37)27.3 (23 to 31)
Day 1542.5 (34 to 53)34.5 (28 to 40)28.3 (22 to 35)31 (27 to 38)
Day 3040.8 (33 to 49)33 (25 to 38)28.7 (20 to 38)32.7 (29 to 39)
Day 6038.5 (34 to 46)35.3 (28 to 44)30 (21 to 39)29.3 (22 to 33)
Day 9037 (30 to 51)36 (21 to 47)27 (16 to 39)25 (21 to 28)
Day 13536 (22 to 46)31.7 (26 to 39)32 (27 to 37)22 (19 to 25)
Day 18036 (33 to 40)38.7 (30 to 52)32.3 (24 to 44)33.7 (31 to 36)
SecondaryCmax of JK07

Maximum concentration from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

Time frame:
Baseline to 60 days
Reported as:
Geometric mean · ng/mL
Cmax of JK07
ng/mLJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3
Cmax of JK07497 ± 44.31680 ± 20.95170 ± 13.8
Secondaryt1/2 of JK07

Half-life from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.

Time frame:
Baseline to 60 days
Reported as:
Geometric mean · h
t1/2 of JK07
hJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3
t1/2 of JK078.11 ± 42.710.95 ± 10.818.32 ± 8.2

Adverse events

Collected over Entire study duration (~180 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JK07 - Cohort 10/4 (0%)0/4 (0%)1/4 (25%)
JK07 - Cohort 21/4 (25%)0/4 (0%)3/4 (75%)
JK07 - Cohort 30/3 (0%)1/3 (33.3%)3/3 (100%)
Matching Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching Placebo
Upper Extremity WeaknessMusculoskeletal and connective tissue disorders0/40/41/30/3
Most frequent other events
Showing 10 of 16
Most frequent other events
EventJK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching Placebo
Night sweatsSkin and subcutaneous tissue disorders0/40/41/30/3
Muscle painMusculoskeletal and connective tissue disorders0/40/41/30/3
Bilateral shoulder painMusculoskeletal and connective tissue disorders0/40/41/30/3
Urinary tract infectionInfections and infestations0/40/41/30/3
Brachial neuritis of both upper extremitiesNervous system disorders0/40/41/30/3
Elevated creatinineInvestigations0/40/41/30/3
Myalgia and arthralgiaMusculoskeletal and connective tissue disorders0/40/41/30/3
Neuropathy exacerbationNervous system disorders0/40/41/30/3
Elevated liver enzymesInvestigations0/40/40/31/3
Left arm nerve painNervous system disorders0/40/40/31/3

Baseline characteristics

This was an ascending dose phase 1 trial. Participants were enrolled in an ascending fashion lower to higher doses of JK07.

Age, Categorical
Age, Categorical(Participants)JK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching PlaceboTotal
<=18 years00000
Between 18 and 65 years421310
>=65 years02204
Age, Continuous
Age, Continuous(years)JK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching PlaceboTotal
Mean53.3 ± 10.961.3 ± 9.7461.0 ± 14.9354.3 ± 5.1357.4 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)JK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching PlaceboTotal
Female02114
Male422210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching PlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American01012
White433212
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)JK07 - Cohort 1JK07 - Cohort 2JK07 - Cohort 3Matching PlaceboTotal
United States443314
08

Study locations

7 sites
  • University of Arizona College of Medicine
    Tucson, Arizona 85724-5039, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Harvard Medical School/ Massachusetts General Hospital
    Boston, Massachusetts 02114-2696, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health Science University Hospital
    Portland, Oregon 97239, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Tang WHW, Steiner J, Kassi M, Wheeler MT, Spahillari A, Sweitzer NK, Grodin JL, Solomon N, Singhal S, McEwen AMG, Murphy SL. Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction. JACC Basic Transl Sci. 2025 Sep;10(9):101352. doi: 10.1016/j.jacbts.2025.101352. Epub 2025 Jul 29. PubMed 40737710 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jun 2023, 32 months.

Results were first posted in Jul 2025, 2 years 1 month after primary completion.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 32 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 24, 2019
StartActual
Sep 21, 2020
Primary completionActual
Jun 8, 2023
CompletionActual
Jul 7, 2023
Results first posted
Jul 9, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04210375
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Sep 21, 2020
Primary completion
Jun 8, 2023
Completion
Jul 7, 2023
Results posted
Jul 9, 2025
Last update
Jul 9, 2025

Study contacts

Wilson Tang, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JK07

Start the discussion